Parathyroid Hormone (1-34)-Coated Microneedle Patch System: Clinical Pharmacokinetics and Pharmacodynamics for Treatment of Osteoporosis
Autor: | Yuh-Fun Maa, Peter E. Daddona, Jaap W. Mandema, James A. Matriano |
---|---|
Rok vydání: | 2010 |
Předmět: |
Adult
Time Factors Injections Intradermal Microinjections Osteoporosis Pharmaceutical Science Parathyroid hormone Pharmacology Placebo Drug Administration Schedule Drug Delivery Systems Pharmacokinetics Teriparatide Humans Medicine Tissue Distribution Pharmacology (medical) Osteoporosis Postmenopausal Aged Transdermal Aged 80 and over Bone mineral Bone Density Conservation Agents Dose-Response Relationship Drug business.industry Organic Chemistry Equipment Design Middle Aged medicine.disease Treatment Outcome Needles Pharmacodynamics Molecular Medicine Female business Biotechnology medicine.drug |
Zdroj: | Pharmaceutical Research. 28:159-165 |
ISSN: | 1573-904X 0724-8741 |
DOI: | 10.1007/s11095-010-0192-9 |
Popis: | To evaluate the clinical PK/PD of PTH(1-34) delivered by a novel transdermal drug-coated microneedle patch system (ZP-PTH) for the treatment of osteoporosis.Phase 1 PK studies evaluated the effect of site of administration, patch wear time and dose in normal volunteers, ages 40-85 yrs. Phase 2 was conducted in post-menopausal women with osteoporosis to determine the patch dose response compared to placebo patch and FORTEO® injection.Phase 1 ZP-PTH patch delivery demonstrated a rapid PTH plasma pulse profile with T(max) 3 times shorter and apparent T(1/2) 2 times shorter than FORTEO®. In Phase 2, ZP-PTH 20, 30 and 40 µg doses showed a proportional increase in plasma PTH AUC. Inter-subject and intra-subject AUC variability was similar for all patch doses and comparable to injection. All patch doses produced a significant increase in spine bone mineral density. Unexpectedly, ZP-PTH also produced an early increase in hip bone mineral density, an effect not observed with the injection.These studies suggest that this novel ZP-PTH patch system can deliver a consistent and therapeutically relevant PTH PK profile. Based on encouraging Phase 2 safety and efficacy data, the program is advancing into a pivotal Phase 3 clinical study. |
Databáze: | OpenAIRE |
Externí odkaz: |